Oxford Biomedica and Novartis extend lentiviral vector manufacturing agreement
The new agreement extends to 2028 and allows Oxord Biomedica to work with other potential partners across all CAR-T targets
Building on its established relationship with Novartis, Oxford Biomedica has signed an updated and extended commercial supply agreement with Novartis.
Back in 2014, Oxford Biomedica licensed its LentiVector platform — a lentiviral-based gene delivery system — to Novartis in the field of CAR-T.
This was followed by a five-year commercial supply agreement, which the two companies signed in December 2019.
The two companies have now extended the terms of their agreement to the end of 2028 which will see Oxford Biomedica work on multiple CAR-T programs with Novartis, including Kymriah — a gene therapy product for treating two types of blood cancer .
Through the agreement, Oxford Biomedica has also regained the rights to its LentiVector platform relating to three CAR-T targets, including CD19-targeted therapies, which will help the company to maximise its ability to serve a larger proportion of the lentiviral vector market.
The company hasn't been slow to respond with its newly acquired rights as it has also signed a new licence and supply aggrement with Arcellx — a Gaithersburg MD-based biotechnology company developing novel, adaptive and controllable cell therapies for the treatment of patients with cancer and autoimmune diseases.
Furthermore, Oxford Biomedica has also been granted additional flexibility in ordering of GMP batches across its multiple GMP facilities, meaning it no longer has a minimum order commitment.
According to John Dawson, Chief Executive Officer of Oxford Biomedica, this flexibility will allow the company to react to the "rapidly growing dtnamics of of the commercial CAR-T sector".
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance